Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Insight Pharma Reports | European Clinical Trial Site Options: An Insider’s Analysis Overview

European Clinical Trial Site Options: An Insider’s Analysis Overview

Author: Pavle Vukojevic, MD

A vast new opportunity for clinical trials has emerged in Europe as a result of the collapse of the Soviet Union and events during the last decade of the 20th century. The result is the emergence of dozens of sovereign countries and gone is the political dividing line between East and West Europe. Now these countries join the countries of Western Europe as well as the CIS to offer a spectrum of clinical trial options. Among these are:

* Treatment-naïve populations

* Ease of patient recruiting

* Superb trial administration

* Lower costs

* Applicable EMEA standards or equivalents

European Clinical Trial Site Options: An Insider’s Analysis, authored by a CRO executive living in Serbia, provides a penetrating review and summation on the state of and opportunities for clinical trial programs in 44 countries organized into three categories.

* EU Member States and applicants

* Non EU affiliated states

* Membership of the CIS

A standardized template is employed to summarize the salient aspects for each country. The information includes:

* Geographic and population information

* Recent political history and religious demographics

* Type of healthcare system, its funding and distribution

* Regulatory structure governing clinical trials

* Policies, procedures, timelines and fee structures for single and multi-site clinical trial applications

* Past clinical trial history and FDA inspection data if available

* Quality of medical staff training, English proficiency, and clinical interest

* Plus–“insider” comments on the pros and cons to expect

The clinical trials industry in the developed countries in Europe is a mature and expensive option. Most of these populations are treatment savvy and due to competition patient recruiting can be difficult and time consuming. These considerations have driven companies to consider India and China as sites for clinical trials. However, differences in medical practices and training as well as problems with English language fluency can become extremely problematic. The current definition of Europe, all territory west of the Urals, has opened the opportunities for clinical trials.

About the Author

Pavle Vukojevic, MD, is Vice President, Medical Affairs for Pharm-Olam International. He received his MD degree from Belgrade University and served as a consulting rheumatologist in Belgrade for over 10 years. Dr. Vukojevic has been involved in clinical research trials for over 15 years and has experience in all phases and with many indications. In 2001, he joined Pharm-Olam and has been involved in setting up the Pharm-Olam Int. Representative Office in Serbia and Montenegro. As the Regional Director of Operations for Pharm-Olam International, he coordinates operations, recruitment, and practical training for all new CRAs in neighboring countries. Dr. Vukojevic founded ACRP in Serbia and was chapter president until recently.

Length 250 pages Date published December 2008
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions